跳到正文
原文
ClinicalTrials.gov 临床试验·· 22 天前AI 评分38

MyeloMATCH II期试验:比较 ASTX727+venetoclax 联合或不联合 enasidenib 治疗 IDH2 突变新诊断 AML

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

AI 导读

MyeloMATCH II期试验正在评估 ASTX727 联合 venetoclax 加用或不加用 enasidenib,用于治疗 IDH2 突变的新诊断急性髓系白血病(AML)老年患者或不适合标准治疗的年轻患者。

来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov